Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Protein Page:
FOXL2 (human)
p Phosphorylation
ac Acetylation
me Methylation
m1 Mono-methylation
m2 Di-methylation
m3 Tri-methylation
ub Ubiquitination
sm Sumoylation
ne Neddylation
gl O-GlcNAc
ga O-GalNAc
pa Palmitoylation
ad Adenylylation
sn S-Nitrosylation
ca Caspase cleavage
sc Succinylation

Overview
FOXL2 Transcriptional regulator. Critical factor essential for ovary differentiation and maintenance, and repression of the genetic program for somatic testis determination. Prevents trans- differentiation of ovary to testis through transcriptional repression of the Sertoli cell-promoting gene SOX9. Has apoptotic activity in ovarian cells. Suppresses ESR1-mediated transcription of PTGS2/COX2 stimulated by tamoxifen. Is a regulator of CYP19 expression. Participates in SMAD3-dependent transcription of FST via the intronic SMAD-binding element. Is a transcriptional repressor of STAR. Activates SIRT1 transcription under cellular stress conditions. Activates transcription of OSR2. Defects in FOXL2 are a cause of blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES); also known as blepharophimosis syndrome. It is an autosomal dominant disorder characterized by eyelid dysplasia, small palpebral fissures, drooping eyelids and a skin fold running inward and upward from the lower lid. In type I BPSE (BPES1) eyelid abnormalities are associated with female infertility. Affected females show an ovarian deficit due to primary amenorrhea or to premature ovarian failure (POF). In type II BPSE (BPES2) affected individuals show only the eyelid defects. There is a mutational hotspot in the region coding for the poly-Ala domain, since 30% of all mutations in the ORF lead to poly-Ala expansions, resulting mainly in BPES type II. Defects in FOXL2 are a cause of premature ovarian failure type 3 (POF3). An ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. Note: This description may include information from UniProtKB.
Protein type: Transcription factor; DNA binding protein
Cellular Component: nucleus
Molecular Function: protein binding; DNA binding; ubiquitin conjugating enzyme binding; sequence-specific DNA binding; caspase regulator activity; estrogen receptor binding; transcription factor activity
Biological Process: transcription from RNA polymerase II promoter; embryonic eye morphogenesis; positive regulation of apoptosis; positive regulation of transcription, DNA-dependent; female somatic sex determination; positive regulation of caspase activity; ovarian follicle development; positive regulation of transcription from RNA polymerase II promoter; DNA fragmentation during apoptosis; cell differentiation; menstruation; extraocular skeletal muscle development; negative regulation of transcription, DNA-dependent; granulosa cell differentiation
Reference #:  P58012 (UniProtKB)
Alt. Names/Synonyms: BPES; BPES1; forkhead box L2; Forkhead box protein L2; forkhead transcription factor FOXL2; FOXL2; PFRK; PINTO; POF3
Gene Symbols: FOXL2
Molecular weight: 38,772 Da
Basal Isoelectric point: 9.26  Predict pI for various phosphorylation states
Select Structure to View Below

FOXL2

Protein Structure Not Found.


STRING  |  neXtProt  |  Protein Atlas  |  BioGPS  |  DISEASE  |  Scansite  |  Pfam  |  Phospho.ELM  |  NetworKIN  |  Source  |  UCSD-Nature  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene


Sites Implicated In
intracellular localization: S33‑p, S326‑p

Modification Sites and Domains Show Modification Legend
Click here to view phosphorylation modifications only

Modification Sites in Parent Protein, Orthologs, and Isoforms Show Modification Legend
 

Show Multiple Sequence Alignment


 SS 

SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


 MS 

MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


       human

 
1 1 S4-p ____MMAsyPEPEDA
1 1 Y5-p ___MMAsyPEPEDAA
1 0 K25-sm PETGRTVkEPEGPPP
2 4 S33-p EPEGPPPsPGKGGGG
0 1 Y81-p RLTLSGIyQyIIAKF
0 1 Y83-p TLSGIyQyIIAKFPF
0 1 Y91-p IIAKFPFyEKNKkGW
1 1 K96-ac PFyEKNKkGWQNSIR
0 2 Y127-p GGERKGNyWTLDPAC
1 1 K140-ac ACEDMFEkGNYRRRR
1 1 S211-p WPLPQPPsPMPyASC
1 1 Y215-p QPPsPMPyASCQMAA
1 1 S238-p AAAAGPGsPGAAAVV
0 2 Y258-p PAASYGPyTRVQSMA
1 1 S323-p APPPGQLsPAsPAtA
1 1 S326-p PGQLsPAsPAtAAPP
1 1 T329-p LsPAsPAtAAPPAPA
1 1 K366-ac SYWDHDSkTGALHSR
  mouse

 
S4 ____MMASYPEPEDT
Y5 ___MMASYPEPEDTA
K25 PESGRAVKEAEASPP
S33 EAEASPPSPGKGGGT
Y77 RLTLSGIYQYIIAKF
Y79 TLSGIYQYIIAKFPF
Y87 IIAKFPFYEKNKKGW
K92 PFYEKNKKGWQNSIR
Y123 GGERKGNYWTLDPAC
K136 ACEDMFEKGNYRRRR
S207 WPLPQPPSPMPYASC
Y211 QPPSPMPYASCQMAA
S234 AAAAGPGSPGAAAVV
Y254 PAASYGPYSRVQSMA
S322 APPPGQLSPASPATA
S325 PGQLSPASPATAAPP
T328 LSPASPATAAPPAPA
K365 SYWDHDSKTGALHSR
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.